About Pharma Industry

BNET Pharma provides daily industry trends and news coverage with insights for managers and executives about major manufacturers of pharmaceuticals and medicine. In addition to detailed drug company profiles, we bring you industry analysis on new partnerships, drug patents and products, cost management, investments, pharmaceutical related lawsuits, and a host of other important business issues.

Former CellCyte Execs Sued by SEC for Role in Pump and Dump Stock Scheme

By Trista Morrison | Sep 10, 2009

In case you were wondering why counsel always cuts the hype out of your press releases…CellCyte Genetics and its former top execs got slapped with an SEC lawsuit for their role in a hype-driven pump-and-dump stock scheme.

Stem cell player CellCyte ran into trouble when it teamed up with investor G. Brent Pierce, who had already been barred from trading in Canada because of his role in pumping and dumping stocks like Lexington Resources and Morgan Creek Energy. You’d think that might have raised a red flag with CellCyte, but CEO Gary Reys told the Seattle Times that his lawyers had investigated Pierce and found nothing wrong.

Pierce blasted out hypey newsletters and brochures claiming CellCyte’s technology “truly could be the most astonishing and important medical breakthrough in your lifetime!” and that the stock “could be the chance of your lifetime to turn $10,000 into $4 million, maybe even $15 million!” CellCyte’s shares rocketed from $4 to $7.50 – but Reys told the Times the activity was simply an “amazing” show of investor confidence.

CellCyte’s stock is now trading at four cents. It had $923 in cash as of June 30 and is basically in limbo, trying to fundraise and figure out if the technology it licensed from the government is worth a crap or not.

And this week the SEC sued CellCyte, Reys and former CSO Ronald Berninger for “for falsely telling investors that the company’s cutting-edge stem cell technology had been proven successful” and was cleared for clinical trials.

According to the SEC press release:

CellCyte did not know how to properly formulate the stem cell compound, had never attempted experiments with the compound to repair organs, and had not satisfied any of the FDA requirements to begin human clinical trials.

And while the company claimed it had no control over Pierce, the SEC said Berninger approved the misleading statements and Reys approved fraudulent SEC filings.

CellCyte and Berninger agreed to a settlement, accepting a permanent injunction without admitting or denying guilt. Berninger also agreed to pay a $50,000 penalty and be barred from serving as an officer or director of a public company for five years.

Reys case is still pending.

Jail photo by Flickr user D.C.Atty, CC

Trista Morrison is a staff writer at BioWorld Today, a daily newspaper that's been covering the biotech industry about as long as there's been a biotech industry to cover.

BNET User Analysis

Web Buzz:
  • SEC Charges Start-up Biotech Company with Securities Fraud

    Securities Law Prof Blog - 77 days 7 hours 55 minutes ago

    « SEC Charges North Carolina Couple of Bilking Senior Citizens | Main | Ohio AG Announces $475 Million Settlement with Merrill Lynch Is Final » The SEC charged CellCyte Genetics Corporation, a biotechnology company based in Bothell, Wash., and its former CEO and Chief Scientific Officer, for falsely telling investors that the company's...

  • SEC sues CellCyte, former execs for lying to investors

    FierceMarkets - 77 days 8 hours 24 minutes ago

    The SEC has filed a lawsuit against Bothell, WA-based CellCyte Genetics and two former executives for lying to investors regarding its stem cell therapies. The developer has already been in hot water with German regulators and its shareholders after a public relations blitz in 200 7 sent its stock price soaring from $4.00 to $7.50 and...

  • How To Effectively Use Your Cell Phone After An Earthquake

    Information Week - 41 days 7 hours 18 minutes ago

    Verizon Wireless periodically sends out press releases with information so banal, you have to wonder why it wastes the time and effort. The information it shares today -- about how best to use your cell phone after an earthquake -- is actually pretty useful

  • Conde Nast Ad Revenue Fell $1 Billion This Year

    Silicon Alley Insider - 47 days 10 hours 39 minutes ago

    In case there's any confusion about why Condé Nast is cutting magazines and staff, Newsweek clears it up : Through August, ad dollars already have plunged by about $600 million from the similar eight-month period in 2008 when revenues also were depressed. Of Condé Nast's two dozen magazines, among them some of publishing's glossiest titles,...

  • Steve Jobs profile shows our obsession with the cult of personality

    VentureBeat - 99 days 5 hours 44 minutes ago

    Imagine the pain at Microsoft and Intel. Steve Jobs doesn’t have to do anything, and he gets outstanding press coverage. In the doldrums of August, he can hide out in his corporate offices at Cupertino and still become the focus of a major story. The four-part profile of Apple’s chief executive in Sunday’s Financial Times is proof about...

 
Reply to Story

BNET TalkbackShare your ideas and expertise on this topic

Subscribe to this discussion via Email or RSS

  •  
    1

    Andres Ruiz

    09/14/09 | Report as spam

    RE: Former CellCyte Execs Sued by SEC for Role in Pump and Dump Stock Schem

    Hello, I am a foreign investor of CCYG since I read a very
    interesting insert in USA Today in November 2007, but I?ve
    realized this was misleading information. I invested $10,000 that
    now is worth $120. I feel totally cheated. If somebody can help me
    understand if there's anything I can do to recover part of my
    investment would be highly appreciated.
    Andres Ruiz
    jaruizt@gmail.com

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)

advertisement
Click Here
advertisement
  • Click Here
  • Click Here
  • Click Here
advertisement